47 results
8-K
EX-10.1
FBIO
Fortress Biotech Inc
3 Jan 24
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:10pm
on Schedule 3.1(hh), there is no pending, completed or, to the Company's knowledge, threatened, in writing, regulatory action (including any lawsuit
424B5
FBIO
Fortress Biotech Inc
2 Jan 24
Prospectus supplement for primary offering
5:59pm
subsidiary of Fortress that was sold to AstraZeneca’s Alexion (“Alexion”) in October 2021, is the defendant in a lawsuit brought by The University
8-K
EX-10.1
x3d0vmrh908 9s
14 Nov 23
Fortress Biotech Announces Launch of Proposed Public Offering
4:11pm
424B5
c3uev4pka81fy sj8
13 Nov 23
Prospectus supplement for primary offering
5:16pm
424B5
ie1yi7d
9 Nov 23
Prospectus supplement for primary offering
5:02pm
CORRESP
aaq5ba8
26 Oct 23
Correspondence with SEC
12:00am